The analysis suggests this target is achievable due to the strong performance of its Vera Rubin product line, expected hyperscaler capital expenditure reaching $1.3 trillion in 2027, and a projected 70% revenue growth for FY28. The stock is currently trading at approximately $229.77, implying a 52.3% gain to reach the target.